Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia.
Hepatitis C virus (HCV) infection is often associated to extrahepatic manifestations while these are less common in HBV infections. Reported cases of mixed cryoglobulinemia (MC) related to HBV infection are very rare: the exact prevalence of this extrahepatic manifestation has not yet been established and the optimal treatment is unclear (no guideline indications are available). We propose an explorative evaluation of treatment of MC HBV-related with telbivudine (LdT) in a small group of patients affected by chronic hepatitis B (CHB). We included 7 patients affected by CHB naive for previous treatment. We administered a single dose of 600mg/day of LdT. ALT levels, HBV-DNA, CD4+/CD8+ ratio and cryocrit were monthly measured. We evaluated the efficacy of 1 year-treatment with LdT on the cryocrit and MC-related symptoms. We observed a significant decrease of cryocrit (p=0.002) and HBV-DNA (p=0.001) during the treatment; CD4+/CD8+ ratio increased (p=0.002) after 1 year. Five patients did not show symptoms and two patients with necrotizing vasculitis have reported a significant clinical improvement with only residual paresthesias. No exacerbations were observed. We consider LdT a suitable option for the treatment of MC HBV-related.